Clear Search

Showing 71 results for “systemic”.

November 2022

Belimumab Use During Pregnancy: Interim Results of the Belimumab Pregnancy Registry

Birth Defects Res. 2022. Epub ahead of print doi: 10.1002/bdr2.2091

There was no pattern or common mechanism of birth defects associated with belimumab within the Belimumab Pregnancy Registry (BPR) data.

more…

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus

N Engl J Med. 2022;387(10):894–904 doi: 10.1056/NEJMoa2118025

Phase 2 study, in patients with systemic lupus erythematosus, shows that litifilimab is associated with a greater reduction from baseline in the number of swollen and tender joints than placebo, over a period of 24 weeks.

more…

October 2022

Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature

Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188

Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.

more…

June 2022

Biological impact of iberdomide in patients with active systemic lupus erythematosus

doi: 10.1136/annrheumdis-2022-222212

Phase 2b study evaluating the pharmacodynamics and pharmacokinetics of oral iberdomide in patients with active SLE demonstrates that iberdomide significantly improves lupus disease activity and reduces hallmarks of the immunopathogenesis of SLE.

more…

March 2022

Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index

Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keab883

Easy-BILAG is a high-accuracy, time-efficient tool for recording BILAG-2004 disease activity in systemic lupus erythematosus (SLE).

Disease activity measurements in SLE are necessary for optimal patient care, treat-to-target approaches and clinical guidelines. However, administrative burden and potential frequency of errors with the current comprehensive disease activity instrument (BILAG-2004) limits its use in routine practice.

more…